autologous blood and marrow transplantation - Blog Science ...

oba
Q.
1.0
0.9
Dicke et al.
Stage IV Breast Cancer
CAT C Survival
'"I..
n = 34
Alive = 2
0.8 1 . Med Survival = 13 months
0.7
0.6
0.5
0.4
—
0.3 —
0.2
—
0.1 —
"I
L,
L,
n
_ _
] u
! 1
1 .
, 1
0.0 1 1 1
1 1 1 1 1 1 1
20
Months From HD To FU
40
337
Median
Figure 5. Survival of category C metastatic breast cancer. On the horizontal axis, the tim
from onset of high dose (HD) to last follow-up has been plotted. N, number of patients un
study; Med Survival, median survival.
breast cancer: Who should be offered alternative initial therapies? Breast Cancer Res Treat
13:33-38, 1989.
3. Spitzer G, Deisseroth A, Ventura G, Jagannath S, Fogel B, Taylor K, Huan S, Dunphy F,
Dicke K, Souza L: Use of recombinant human hematopoietic growth factors and autolo­
gous bone marrow transplantation to attenuate the neutropenic trough of high-dose ther­
apy. Int J Cell Cloning 1:249-261, 1990.
4. Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA,
Jagannath S, Holmes F, Wallerstein RO, Bohannan PA, Dicke KA: Treatment of estro­
gen receptor-negative or hormonally refractory breast cancer with tandem high dose
chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207-1216,1990.
5. Hood DL, Dicke KA, Donneil PJ, Sowell LK, Fulbright LK: Cytokeratin labeling with
flow cytometry analysis to detect minimal disease in the marrow and blood of breast and
lung cancer patients (Abstract). Tandem BMT Meeting, Keystone, CO, February
28-March 3, 1999.
6. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone
AH, Gorin NC, Flesh M, LaPorte JP, Maraninchi D, Pico J, Bosly A, Anderson C, Schots
R, Biron P, Cabanillas F, Dicke KA: High dose therapy and autologous bone marrow trans­
plantation after failure of conventional chemotherapy in adults with intermediate grade or
high grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987.